Empamet
Generic Name
Empagliflozin
Manufacturer
Local Pharma Co. Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| empamet 5 mg tablet | ৳ 23.00 | ৳ 184.00 |
Description
Overview of the medicine
Empamet 5 mg Tablet contains Empagliflozin, an oral medication used to lower blood sugar in adults with type 2 diabetes mellitus. It also reduces the risk of cardiovascular death and hospitalization for heart failure in certain patient populations.
Uses & Indications
Dosage
Adults
Initial dose is 10 mg once daily, taken in the morning, with or without food. May be increased to 25 mg once daily based on glycemic control and tolerability. For heart failure, 10 mg once daily.
Elderly
No dose adjustment is required based on age alone. However, renal function should be assessed before starting and during treatment.
Renal_impairment
Not recommended for initiation in patients with eGFR less than 30 mL/min/1.73m² for glycemic control indication, or eGFR less than 20 mL/min/1.73m² for heart failure indication. If eGFR falls below 30 mL/min/1.73m² during treatment for T2DM, consider discontinuing Empagliflozin.
How to Take
Take orally once daily in the morning, with or without food.
Mechanism of Action
Empagliflozin selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
Pharmacokinetics
Onset
Within hours for glucose lowering.
Excretion
Excreted about equally via the kidneys and bile/feces. Approximately 50% renally excreted and 50% fecally excreted.
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations are reached in 1.5 hours.
Metabolism
Primarily metabolized by glucuronidation via UGT enzymes (UGT2B7, UGT1A3, UGT1A8, UGT1A9).
Side Effects
Contraindications
- •Hypersensitivity to empagliflozin or any component of the formulation
- •Severe renal impairment (eGFR < 30 mL/min/1.73m² for glycemic control indication, or eGFR < 20 mL/min/1.73m² for heart failure indication)
- •End-stage renal disease
- •Dialysis
Drug Interactions
Lithium
May decrease lithium plasma concentration by increasing renal excretion of lithium.
Diuretics
Increased risk of dehydration and hypotension.
Insulin/Sulfonylureas
Increased risk of hypoglycemia when used in combination; dose adjustments may be needed.
Storage
Store below 30°C, in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose of empagliflozin can lead to symptoms like dehydration, electrolyte imbalance, and hypoglycemia (especially with concomitant insulin/sulfonylureas). Treatment is supportive and symptomatic.
Pregnancy & Lactation
Not recommended during the second and third trimesters of pregnancy. Avoid use during lactation as it is unknown if empagliflozin is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by FDA and other regulatory bodies worldwide
Patent Status
Patent status varies by region
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
